Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

Vaccine

Volumn 14, Issue 5, 1996, Pages 435-438

  Klugman, Keith P ^a   Koornhof, Hendrik J ^a   Robbins, John B ^b   Le Cam, Nancy N ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Pasteur Merieux Serums et Vaccins   (France)

Author keywords

Salmonella typhi; Typhoid vaccine; Vi capsular polysaccharide

Indexed keywords

POLYSACCHARIDE; SALMONELLOSIS VACCINE; TYPHOID VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SALMONELLA TYPHI;

EID: 0029881198     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00186-5     Document Type: Article

References (9)

1. Klugman, K.P., Gilbertson, I.T., Koornhof, H.J. et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987, ii, 1165-1169
2. Acharya, I.L., Lowe, Ch.U. et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N. Engl. J. Med. 1987, 317, 1101-1104
3. Klugman, K.P., Vosloo, H., Arntzen, I. and Koornhof, H.J. Prevention of typhoid fever by single capsular polysaccharide vaccination - two-year-results. In: Travel Medicine (Eds Steffen, R., Lobel, H.O., Hayworth, J. and Bradley, D.J.). Springer, Berlin, 1989, pp. 243-247
4. Tacket, C.O., Ferrecio, C., Robbins, J.B. et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J. Infect. Dis. 1986, 154, 342-345
5. Farr, R.S. A quantitative immunochemical measure of the primary interaction between I* Bsa and antibody. J. Infect. Dis. 1958, 103, 239-262
6. Landy, M. and Lambe, E. Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc. Soc. Exp. Biol. Med. 1953, 82, 593-598
7. Tacket, C.O., Levine, M.M. and Robbins, J.B. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine 1988, 6, 307-308
8. Keitel, W.A., Bond, N.L., Zahradnik, J., Cramton, T.A. and Robbins, J.B. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide-vaccines. Vaccine 1994, 12, 195-199
9. Szu, S.C., Taylor, D.N., Trofa, A.C. et al. Laboratory and preliminary clinical characterisation of Vi polysaccharide-protein conjugate vaccines. Infect. Immun. 1994, 62, 4440-4444